Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aegis Therapeutics, a drug delivery technology company, has received new US patent that provides broad protection for stabilized human growth hormone formulations.
Subscribe to our email newsletter
The Aegis ProTek technology has been employed to create stabilized formulations of human growth hormone (hGH), insulin, antibodies, and other protein drugs that remain unchanged even after continuous agitation for many weeks or months at elevated temperatures.
The patented formulations are said to be suitable for intranasal delivery via a simple metered nasal spray as well as by standard injection or external drug infusion pump.
Aegis ProTek technology is expected to provide patients with safer, more convenient, non-injectable delivery options while extending the effective patent life of hGH and other protein drugs.
Human growth hormone is a recombinant protein drug used in the treatment of pediatric and adult patients who have inadequate secretion of normal endogenous growth hormone.